Egle, Takeda collaborate on anti-Treg immunotherapies

By The Science Advisory Board staff writers

June 11, 2020 -- Egle Therapeutics has formed a strategic research alliance with Takeda Pharmaceutical to validate novel regulatory T-cell (Treg) targets, against which Takeda will develop potential therapies.

Egle was spun out of Institut Curie, and has developed a proprietary target discovery engine that uses patient samples to map unique transcriptomic signatures at single-cell resolution. The system will help identify targets for specific tumor-infiltrating Treg subpopulations.

The company is building a Treg-modulating drug pipeline that also includes resurfaced interleukin-2 (IL-2) proprietary variants with unique mechanisms of action to engage or disengage Tregs.

Under the agreement, Egle will lead target validation efforts on a subset of targets and Takeda will be responsible for the development, manufacturing, and commercialization of resulting therapies. Egle will receive an upfront payment and research funding and will be eligible to receive additional development and sales milestone payments.

Additionally, Takeda will invest $5.2 million in convertible debt through its venture arm to support Egle's corporate growth and internal IL-2-based Treg modulation programs.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.